MXPA04000339A - MeTODOS PARA REDUCIR INMUNOGENICIDAD DE POLIPePTIDOS. - Google Patents

MeTODOS PARA REDUCIR INMUNOGENICIDAD DE POLIPePTIDOS.

Info

Publication number
MXPA04000339A
MXPA04000339A MXPA04000339A MXPA04000339A MXPA04000339A MX PA04000339 A MXPA04000339 A MX PA04000339A MX PA04000339 A MXPA04000339 A MX PA04000339A MX PA04000339 A MXPA04000339 A MX PA04000339A MX PA04000339 A MXPA04000339 A MX PA04000339A
Authority
MX
Mexico
Prior art keywords
polypeptides
modified
methods
reducing immunogenicity
therapeutic
Prior art date
Application number
MXPA04000339A
Other languages
English (en)
Inventor
Carter Graham
Original Assignee
Merck Patent Gesellscahft Mit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gesellscahft Mit filed Critical Merck Patent Gesellscahft Mit
Publication of MXPA04000339A publication Critical patent/MXPA04000339A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Abstract

La presente invencion se refiere al campo de la inmunologia y de la terapeutica con proteinas. Las proteinas terapeuticas son polipeptidos que se administran especialmente a seres humanos. Los polipeptidos son modificados, con lo cual las modificaciones dan como resultado una menor tendencia a que el polipeptido induzca una respuesta inmunitaria despues de su administracion a un sujeto humano. Por lo tanto, la presente invencion proporciona metodos para el desarrollo de polipeptidos terapeuticos que son menos inmunogenicos que cualquier otra contraparte no modificada, cuando se utilizan in vivo. Las modificaciones utilizadas de conformidad con la presente invencion se refieren, por ejemplo a la introduccion de sitios de rompimiento de proteasa, a la union de diferentes moleculas o a la insercion de aminoacido no naturales.
MXPA04000339A 2001-07-13 2002-07-12 MeTODOS PARA REDUCIR INMUNOGENICIDAD DE POLIPePTIDOS. MXPA04000339A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01117105 2001-07-13
EP01117267 2001-07-17
EP01117271 2001-07-17
PCT/EP2002/007785 WO2003006047A2 (en) 2001-07-13 2002-07-12 Methods for reducing immunogenicity of polypeptides

Publications (1)

Publication Number Publication Date
MXPA04000339A true MXPA04000339A (es) 2004-05-04

Family

ID=27224206

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04000339A MXPA04000339A (es) 2001-07-13 2002-07-12 MeTODOS PARA REDUCIR INMUNOGENICIDAD DE POLIPePTIDOS.

Country Status (11)

Country Link
US (1) US7939295B2 (es)
EP (1) EP1409003A2 (es)
JP (1) JP2004533845A (es)
KR (1) KR20040018459A (es)
CN (1) CN1523996A (es)
BR (1) BR0211091A (es)
CA (1) CA2453406A1 (es)
HU (1) HUP0400340A2 (es)
MX (1) MXPA04000339A (es)
PL (1) PL367329A1 (es)
WO (1) WO2003006047A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066152A1 (en) * 2003-12-30 2005-07-21 The Brigham And Women's Hospital, Inc. Thiophene derivatives for up-regulating hla-dm activity
JP2010530895A (ja) * 2007-06-21 2010-09-16 アンジェリカ セラピューティックス，インク． 修飾毒素
WO2009110944A1 (en) * 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins
PL3260128T3 (pl) * 2010-04-28 2021-02-08 Oncoimmune, Inc. Zastosowanie medyczne rozpuszczalnego CD24
CA2902905A1 (en) 2013-03-15 2014-09-25 Claude Geoffrey Davis Modified toxins
WO2015084986A1 (en) * 2013-12-03 2015-06-11 The Johns Hopkins University Methods of evaluating immunodominant epitopes
MA41842A (fr) * 2015-03-31 2018-02-06 Oblique Therapeutics Ab Nouveaux procédés de sélection d'épitope
GB201617002D0 (en) 2016-10-06 2016-11-23 Oblique Therapeutics Ab Multi-protease method
US11332727B2 (en) 2017-03-14 2022-05-17 The Regents Of The University Of California Method for reducing an immune response by administering an immune evading adeno-associated AAV8 or AAVDJ viral vector

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936249B1 (en) * 1998-04-15 2005-08-30 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same

Also Published As

Publication number Publication date
US7939295B2 (en) 2011-05-10
CN1523996A (zh) 2004-08-25
CA2453406A1 (en) 2003-01-23
HUP0400340A2 (hu) 2004-08-30
JP2004533845A (ja) 2004-11-11
US20040185038A1 (en) 2004-09-23
KR20040018459A (ko) 2004-03-03
PL367329A1 (en) 2005-02-21
WO2003006047A3 (en) 2003-09-25
WO2003006047A2 (en) 2003-01-23
BR0211091A (pt) 2004-06-15
EP1409003A2 (en) 2004-04-21

Similar Documents

Publication Publication Date Title
WO2002074783A3 (en) Modified interferon beta with reduced immunogenicity
WO2002062832A3 (en) Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity
SI1105409T1 (sl) Zascita endogenih peptidov pred peptidazno ucinkovitostjo s konjugacijo na krvne komponente
ATE352559T1 (de) Verfahren zur verminderung der immunogenität von proteinen
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
WO2002062833A3 (en) Modified leptin with reduced immunogenicity
MXPA04000339A (es) MeTODOS PARA REDUCIR INMUNOGENICIDAD DE POLIPePTIDOS.
PL371278A1 (en) Modified factor viii
WO2002062843A3 (en) Modified erythropoietin (epo) with reduced immunogenicity
WO2002085941A3 (en) Modified interferon alpha with reduced immunogenicity
PL362986A1 (en) Modified human granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity
WO2002070698A3 (en) Modified ciliary neurotrophic factor (cntf) with reduced immunogenicity
NZ335633A (en) Production of recombinant H. pylori polypeptides for treatment and diagnosis of H. pylori related diseases
EP1499349A4 (en) RECOMBINANT HYBRID ALLERGENIC CONSTRUCTS WITH REDUCED ALLERGENITY, MAINTAINING THE IMMUNOGENICITY OF NATURAL ALLERGEN
WO2002068469A3 (en) Modified thrombopoietin with reduced immunogenicity
HUP0402334A2 (hu) Módosított humán növekedési hormon
HUP0303430A2 (hu) Csökkentett immunogenitású, módosított protamin
WO2000029434A3 (en) PNEUMOCOCCAL CHOLINE BINDING PROTEINS, CbpG AND CbpD, DIAGNOSTIC AND THERAPEUTIC USES THEREOF
WO2002074808A3 (en) Modified insulin with reduced immunogenicity
BR0207017A (pt) Fator de crescimento ceratinócito modificado (kgf) com imunogenicidade reduzida
WO2002044202A3 (fr) Peptides immunogeniques mutes derives de r9m, polynucleotides les codant et leurs usages therapeutiques
MXPA04004970A (es) Epitopos de linfocitos t en carboxipeptidasa g2.
HK1092162A1 (en) Biologically active peptides comprising isoleucyl-valyl-threonyl- asparaginyl-threonyl-threonine (ivtntt)
AU1390795A (en) Equine arteritis virus peptides, antibodies and their use in a diagnostic test

Legal Events

Date Code Title Description
FA Abandonment or withdrawal